Thursday, June 29, 2017

Theragene Pharmaceuticals Buys Assets From Eiger Biopharmaceuticals

Sorrento Valley-based Theragene Pharmaceuticals and Palo Alto-based Eiger BioPharmaceuticals announced a deal on Thursday, where Eiger would sell its non-strategic assets to Theragene. The two companies said Theragene would pay $3.1M upfront to Eiger, split between $240,000 in cash plus up to $2.85 million in Theragene common stock, plus up to $15M in future milestone payments, royalties, and licensing fees.